Getinge, a Sweden-based healthcare company, has finalized an agreement to acquire Paragonix, a U.S. organ transplant technology developer, in a deal valued at up to $477 million. This acquisition aligns with Getinge's strategic goal of enhancing its global healthcare offerings by addressing critical needs in solid organ transplantation. The integration of Paragonix’s advanced organ preservation systems with Getinge’s resources and global distribution network is expected to expand the reach of these technologies into new markets and drive further innovation in the field.
Paragonix, based in Waltham, Massachusetts, specializes in developing organ preservation systems for liver, heart, pancreas, and lung transplants. Their devices combine stable hypothermic preservation technology with comprehensive digital tools for organ tracking and monitoring. Getinge views this acquisition as a strategic fit that will allow the company to leverage its expertise in acute heart and lung support while expanding Paragonix's market presence through its established global sales network.
The deal is anticipated to accelerate the availability of Paragonix’s technologies, ultimately improving patient outcomes and increasing the number of successful organ transplants worldwide. Dr. Lisa Anderson, Founder, President, and CEO of Paragonix, expressed excitement about the partnership, emphasizing the potential to bring life-changing innovations to underserved patient populations globally. Both companies are optimistic that the acquisition will lead to the development of new technologies addressing critical global healthcare needs.
Click here to read the original news story.